Cardiac isoform of alpha 2 macroglobulin and its reliability as a cardiac marker in HIV patients.

BACKGROUND Cardiac isoform of alpha 2 macroglobulin (CA2M), a serum protein (182000Mr) has been used as a diagnostic molecular marker for cardiac manifestations in HIV and diabetic patients. This study investigates the reliability of CA2M as an early diagnostic marker for cardiac manifestations in HIV patients and factors that could possibly influence their levels. METHODS A total of 206 serum samples were analysed from HIV patients with cardiac diseases (68), with non-cardiac ailments (48), opportunistic infections (34) and without other co-morbidities (56). The immuno-cross-reactivity between human serum CA2M and anti-rat CA2M antibody was tested and quantified by sandwich enzyme linked immunosorbent assay (ELISA). RESULTS The CA2M levels were high in HIV patients with cardiac diseases irrespective of the manifestations. The CA2M levels were not influenced by opportunistic infections, non-cardiac ailments and patient parameters like age, sex, duration of illness, past history of other co-morbidities. CONCLUSION CA2M can be used as a reliable early diagnostic marker in HIV patients with cardiac manifestations. CA2M levels were not influenced by other patient parameters.

[1]  E. Harlow,et al.  Antibodies: A Laboratory Manual , 1988 .

[2]  G. Selvam,et al.  Cardiac isoform of alpha 2 macroglobulin, an early diagnostic marker for cardiac manifestations in AIDS patients , 2006, AIDS.

[3]  S. Sadayappan,et al.  Cardiac isoform of alpha-2 macroglobulin--a new biomarker for myocardial infarcted diabetic patients. , 2006, Atherosclerosis.

[4]  G. Selvam,et al.  Cardiac isoform of alpha-2 macroglobulin as a novel diagnostic marker for cardiac diseases , 2005, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[5]  G. Barbarini,et al.  Cardiac involvement in the acquired immunodeficiency syndrome: a multicenter clinical-pathological study. Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS Investigators. , 1998, AIDS research and human retroviruses.

[6]  G. Bárbaro.  Cardiovascular manifestations of HIV infection. , 2002, Circulation.

[7]  T. Louis,et al.  Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. , 2003, The New England journal of medicine.

[8]  C. Rajamanickam,et al.  A Novel Serum Protein of Molecular Weight 182 kDa: A Molecular Marker for an Early Detection of Increased Left Ventricular Mass in Patients with Cardiac Hypertrophy , 1998, Journal of cardiovascular risk.

[9]  M. Rajappa,et al.  Biomarkers of Cardiac Injury: An Update , 2005, Angiology.

[10]  N. Selvamurugan,et al.  Purification and characterization of a high-molecular-weight protein induced in rat serum during the development of cardiac hypertrophy. , 1990, Archives of biochemistry and biophysics.

[11]  M. Schluchter,et al.  Left ventricular structure and function in children infected with human immunodeficiency virus: the prospective P2C2 HIV Multicenter Study. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group. , 1998, Circulation.

[12]  E. Orav,et al.  Predictors of cardiac morbidity and related mortality in children with acquired immunodeficiency syndrome. , 2003, Journal of the American College of Cardiology.